Treatment of Kidney Cancer: Current Options for RCC with Divergent Histology with Dr. McGregor
RCC Content Hub
Bradley McGregor, MD, FASCO, Director of Clinical Research, Lank Center of Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, reviews current systemic treatment options for renal cell carcinoma (RCC) with divergent histology, emphasizing that these tumors represent a diverse group of biologically distinct diseases. Dr. McGregor explains how advances in pathology and genomics have transformed understanding of non-clear cell RCC and are driving more rational treatment selection. He reviews historical trials that grouped divergent histologies together and established sunitinib as a modest standard of care. Contemporary data from the PAPMET trial demonstrate superior outcomes with cabozantinib in papillary RCC, while highlighting that mesenchymal-epithelial transition (MET) inhibition is most effective when guided by genomic alterations rather than histology alone. Fumarate hydratase-deficient RCC is discussed as a unique subtype with particularly strong responses to bevacizumab plus erlotinib. The presentation also examines the evolving role of immunotherapy, including data from pembrolizumab monotherapy and the randomized SUNNIFORECAST trial, which shows improved survival with nivolumab plus ipilimumab across multiple histologies. Combination immunotherapy and tyrosine kinase inhibitor (TKI) regimens, including cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, demonstrate consistent response rates across divergent RCC subtypes and are emerging as preferred strategies. Dr. McGregor emphasizes that future progress will depend on genomically driven trials and continued enrollment of patients with rare RCC subtypes. Don’t forget to join the GRU Community: https://grandroundsinurology.com/register/ Follow us on Twitter/X: https://x.com/GRUrology And like and subscribe to us here on YouTube!